BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23037472)

  • 1. The long-term survival of a patient with adenosquamous lung carcinoma harboring EGFR-activating mutations who was treated with gefitinib.
    Iwanaga K; Sueoka-Aragane N; Nakamura T; Mori D; Kimura S
    Intern Med; 2012; 51(19):2771-4. PubMed ID: 23037472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.
    Song Z; Lin B; Shao L; Zhang Y
    J Chin Med Assoc; 2013 Sep; 76(9):481-5. PubMed ID: 23769878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
    Huang SF; Liu HP; Li LH; Ku YC; Fu YN; Tsai HY; Chen YT; Lin YF; Chang WC; Kuo HP; Wu YC; Chen YR; Tsai SF
    Clin Cancer Res; 2004 Dec; 10(24):8195-203. PubMed ID: 15623594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports.
    Shukuya T; Takahashi T; Kaira R; Ono A; Nakamura Y; Tsuya A; Kenmotsu H; Naito T; Kaira K; Murakami H; Endo M; Takahashi K; Yamamoto N
    Cancer Sci; 2011 May; 102(5):1032-7. PubMed ID: 21272159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The efficacy and influence factors analysis of EGFR TKIs on patients with lung adenosquamous carcinoma].
    Zhou SY; Hu XS; Li JL; Wang Y; Liu YT; Xing PY; Yang JL; Lin H; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):776-781. PubMed ID: 30392343
    [No Abstract]   [Full Text] [Related]  

  • 6. EGFR gene mutations in patients with adenosquamous lung carcinoma.
    Powrózek T; Krawczyk P; Ramlau R; Sura S; Wojas-Krawczyk K; Kucharczyk T; Walczyna B; Szumiło J; Szyszka-Barth K; Milecki P; Barinow-Wojewódzki A; Milanowski J
    Asia Pac J Clin Oncol; 2014 Dec; 10(4):340-5. PubMed ID: 24575772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations.
    Yokoyama Y; Sonobe M; Yamada T; Sato M; Menju T; Aoyama A; Sato T; Chen F; Omasa M; Date H
    Int J Clin Oncol; 2015 Dec; 20(6):1122-9. PubMed ID: 25953679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gefitinib for a poor performance status patient with squamous cell carcinoma of the lung harboring EGFR mutation.
    Tanaka K; Hata A; Kida Y; Kaji R; Fujita S; Katakami N; Imai Y
    Intern Med; 2012; 51(6):659-61. PubMed ID: 22449680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
    Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
    Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
    Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
    BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenocarcinoma of the lung with rare insertion mutation in EGFR exon 19 that had partial response to gefitinib: a case report.
    Kozlov V; Karpov I; Kovalenko S; Shamanin V
    Exp Oncol; 2017 Jul; 39(2):155-156. PubMed ID: 29483495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
    Paez JG; Jänne PA; Lee JC; Tracy S; Greulich H; Gabriel S; Herman P; Kaye FJ; Lindeman N; Boggon TJ; Naoki K; Sasaki H; Fujii Y; Eck MJ; Sellers WR; Johnson BE; Meyerson M
    Science; 2004 Jun; 304(5676):1497-500. PubMed ID: 15118125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
    Kim MH; Kim HR; Cho BC; Bae MK; Kim EY; Lee CY; Lee JS; Kang DR; Kim JH
    Lung Cancer; 2014 May; 84(2):196-202. PubMed ID: 24629638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.
    Maemondo M; Minegishi Y; Inoue A; Kobayashi K; Harada M; Okinaga S; Morikawa N; Oizumi S; Tanaka T; Isobe H; Kudoh S; Hagiwara K; Nukiwa T; Gemma A
    J Thorac Oncol; 2012 Sep; 7(9):1417-22. PubMed ID: 22895139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between EGFR Gene Mutations and Lung Cancer: a Hospital-Based Study.
    Matam K; Goud I; Lakshmi M AM; Ravi V; Sridhar K; Vijayanand PR; Chakravarthy S; Prasad SV; Tabassum SN; Shaik NA; Syed R; Alharbi KK; Khan IA
    Asian Pac J Cancer Prev; 2015; 16(16):7071-6. PubMed ID: 26514492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer.
    Yoshida K; Yatabe Y; Park JY; Shimizu J; Horio Y; Matsuo K; Kosaka T; Mitsudomi T; Hida T
    J Thorac Oncol; 2007 Jan; 2(1):22-8. PubMed ID: 17410005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
    Li J; Zhang L; Zhu H; Pan W; Zhang N; Li Y; Yang M
    DNA Cell Biol; 2018 Nov; 37(11):903-908. PubMed ID: 30277797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
    Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
    Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern.
    Wu SG; Chang YL; Hsu YC; Wu JY; Yang CH; Yu CJ; Tsai MF; Shih JY; Yang PC
    Oncologist; 2008 Dec; 13(12):1276-84. PubMed ID: 19060236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
    Yoshioka H; Hotta K; Kiura K; Takigawa N; Hayashi H; Harita S; Kuyama S; Segawa Y; Kamei H; Umemura S; Bessho A; Tabata M; Tanimoto M;
    J Thorac Oncol; 2010 Jan; 5(1):99-104. PubMed ID: 19898258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.